CTXR.US Citius Pharmaceuticals Inc

Healthcare Pharmaceuticals USA Stocks
0.5012 USD
Close of Nov 13, 2026
0.3700 1.54
Market cap
USD 13.8M
P/E
-
P/B
0.21x
ROE
-76.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.

Is CTXR.US undervalued?

Graham number

The Graham number of Citius Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Citius Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Citius Pharmaceuticals Inc yet.

Citius Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammator…

Full company profile